Oxygen Therapeutics: Perfluorocarbons and Blood Substitute Safety

Claudia S. Cohn, Melissa M. Cushing

Research output: Contribution to journalReview articlepeer-review

80 Scopus citations


Current demands over the blood supply in developed and developing nations will compound over time. Red cell substitutes have a promising value proposition for transfusion services, because they hold the promise of increasing the availability of blood products and removing donor and contamination safety risks. In this article, the authors note that existing products suffer from critical shortcomings such as vasoactivity; they also point out that substitutes not based on human blood introduce potentially more complex safety hurdles. The authors discuss the attributes of an ideal blood substitute, and the mechanism and current status of perfluorocarbons; they also review the shortcomings of all oxygen therapeutic products in development today.

Original languageEnglish (US)
Pages (from-to)399-414
Number of pages16
JournalCritical Care Clinics
Issue number2
StatePublished - Apr 2009


  • Blood substitute
  • Hemoglobin-based-oxygen-carrier (HBOC)
  • Perfluorocarbons (PFC)


Dive into the research topics of 'Oxygen Therapeutics: Perfluorocarbons and Blood Substitute Safety'. Together they form a unique fingerprint.

Cite this